AtriCure price target raised to $60 from $58 at Needham

Needham analyst Mike Matson raised the firm’s price target on AtriCure to $60 from $58 and keeps a Buy rating on the shares. The analyst cites the company’s broad-based,Q1 strength, particularly in Open-Heart Ablation and Pain Management. AtriCure’s guidance was also likely conservative, and the company should continue to beat on both the top- and bottom-lines, Needham tells investors in a research note.